Actavis’ Record-Breaking Quarterly Sales Show Success Of Merger Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Strong quarter for generic Mycardis, Lidoderm and Cymbalta spurs 36% increase in pharma product sales, while businesses inherited from Warner Chilcott lead to exponential growth in North American branded product revenue. Firm is getting ready for integration of Forest around mid-year.
You may also be interested in...
Watson Begins Anew As Actavis, Focuses On Organic Growth
The traditionally generic-heavy company now has an expanded global presence and a growing branded business to go with its new name.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.